The FDA approved 20 drugs of note in 2010. Most are pharmacologically similar to others already marketed (see Table 1 ). Among the remainder are two orphan drugs granted approval for Dupuytren disease and n-acetylglutamate synthase deficiency (see Table 2 ) and four "first-in-class" medicines for emergency contraception, lipodystrophy, multiple sclerosis, and rheumatoid arthritis (see Table 3 ). One new approval, eribulin, an antimitotic indicated for breast cancer, is the first drug derived from the sea sponge, Halichondria okadai, and only the third marketed drug to be derived from marine invertebrates (see reference 1 for a discussion of the challenges of harvesting drugs from the sea).
Also noteworthy in 2010:
Brand Name Change: The brand name for dexlansoprazole was changed from KAPIDEX to DEXILANT (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 36, pages 969-971; 12th edition, Chapter 45) to avoid name confusion with CASODEX, (bicalutamide).
Bevacizumab (AVASTIN) does not appear to prolong survival, nor provide sufficient benefit in slowing disease progression, to outweigh the risk to patients with metastatic breast cancer and FDA has proposed withdrawing this (one) indication for the drug (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 51, pages 1378-1379; 12th edition, Chapter 62). A public hearing to provide FDA with additional evidence to confirm that the drug is safe and effective for this indication has been requested.
Dolasetron (ANZEMET) can increase the risk of torsades de pointes and is no longer recommended for chemotherapy-induced nausea and vomiting (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 37, pages 1001-1003; 12th edition, Chapter 46).
Quinine (QUALAQUIN ) can cause life-threatening thrombocytopenia, hemolytic-uremic syndrome, and thrombotic thrombocytopenic purpura. Quinine is no longer recommended for the off-label use for leg cramps (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 39, pages 1035-1038; 12th edition, Chapter 49).
Marketed Unapproved Drugs: FDA granted market approval to 2 previously unapproved marketed drugs. The newly licensed versions are morphine sulfate oral solution concentrate (20 mg/ml), and pancrelipase (PANCREAZE [previously Pancrease MT]) (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 21, pages 563-566 and Chapter 37, pages 1005-1006, respectively; 12th edition chapters 18 and 46 respectively.)
Gemtuzumab (MYLOTARG), a monoclonal antibody (specific for the CD33 antigen) and cytotoxic conjugate, was voluntarily withdrawn from the United States market due to a lack of post-marketing confirmation of a survival benefit for patients with acute myeloid leukemia (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 51, page 1379; 12th edition, Chapter 62). Generic manufacturers have been informed of FDA’s recommendation for healthcare professionals to stop prescribing the drug, but it may be some time before the drug is completely purged from the United States market.
Propoxyphene (DARVON, DARVOCET), FDA approved since 1957, was withdrawn from the United States market due to evidence of risk for serious heart rhythm abnormalities (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 21, pages 573-574; 12th edition, Chapter 18).
Rosiglitazone (AVANDIA, AVANDAMET, AVAGLIM) has been suspended from marketing in Europe and placed on a restricted distribution status in the United States due to post-marketing detection of signals of increased cardiovascular risk (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 60, pages 1639-1640; 12th edition, Chapter 43).
Sibutramine (MERIDIA) was voluntarily withdrawn from the United States market due to the post-marketing detection of increased risks for heart attack and stroke associated with its use for weight loss (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 11, page 305; 12th edition, Chapter 13).
Tamper-resistant OxyContin Formulation: The reformulated OxyContin (sustained action oxycodone) formulation is intended to prevent the medication from being cut, broken, chewed, crushed or dissolved to release medication more rapidly than intended (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 21, pages 563-566 and Table 21-6, page 580; 12th edition, Chapter 18).
Update on the Clinical Impact of USP Heparin Potency Reduction: FDA has clarified that the 10% decrease in anticoagulation activity of heparin products manufactured under the new United States Pharmacopeia (USP) standard adopted in 2009, and originally presumed to be clinically insignificant, may warrant adjustments in heparin dosage and/or more intensive monitoring, particularly in the following situations: (1) extracorporeal membrane oxygenation in pediatric patients, (2) cardiopulmonary bypass, and (3) treatment or prevention of life-threatening thromboses (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 54, pages 1470-1474; 12th edition, Chapter 30).
"Repurposed Drugs": Four established drugs were approved for new purposes or as novel formulations for established purposes (see Table 4 ).
In addition, FDA granted the following significant vaccine and new biologic licenses in 2010:
A photodynamic imaging agent, hexaminolevulinate hydrochloride (CYSVIEW), was licensed for the detection of superficial bladder cancer during cystoscopy.
Quadrivalent human papillomavirus (HPV) vaccine (Gardasil) licensure was extended for children and young adults aged 9 to 26 years to include the prevention of anal cancer and associated precancerous lesions due to HPV types 6, 11, 16, and 18.
A fourth alpha1-proteinase inhibitor (Glassia) was licensed for therapy in patients with emphysema caused by a congenital deficiency of alpha1-antitrypsin.
A new 13-valent pneumococcal conjugate vaccine (Prevnar 13) was licensed as the successor to the 7-valent vaccine, Prevnar (licensed in 2000), to prevent invasive pneumococcal disease and otitis media in children aged 6-weeks to 5-years old.
The first RANK ligand inhibitor, denosumab (PROLIA, XGEVA), was licensed for prevention of skeletal fractures and pain in patients with bone metastases from solid tumors (XGEVA) and for the treatment of postmenopausal osteoporosis (PROLIA) (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 61, page 1658 and figure 16-9, page 1659; 12th edition, Chapter 44).
An autologous cellular immunotherapy, sipuleucel-T (PROVENGE) was licensed for the treatment of metastatic hormone-refractory prostate cancer. The therapy consists of administering autologous prostatic acid phosphatase-presenting cells which have been activated in vitro by granulocyte-macrophage colony-stimulating factor (see Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition Chapter 53, pages 1439-1440; 12th edition, Chapter 37).
An absorbable fibrin sealant patch (TACHOSIL) was licensed for use as an adjunct to hemostasis in cardiovascular surgery when control of bleeding by suture, ligature or cautery, is ineffective or impractical.
Velaglucerase alfa (VPRIV), a glucocerebroside-specific enzyme, was licensed for long-term replacement therapy for patients with type 1 Gaucher disease.
Carglumic acid (Figure 1) (CARBAGLU) is a synthetic structural analogue of N-acetylglutamate (NAG). NAG is a metabolically essential cofactor for the first enzyme in the urea cycle, carbamoyl phosphate synthetase 1 (CPS 1). The urea cycle is the body’s sole endogenous system for the clearance of ammonia. NAG is the product of N-acetylglutamate synthase (NAGS), a mitochondrial enzyme. NAGS deficiency is a very rare genetic disorder with only a few cases reported worldwide. As for other urea cycle disorders, NAGS deficiency is characterized by the triad of hyperammonemia, encephalopathy, and respiratory alkalosis, and is frequently fatal within the first days-to-hours after birth. Carglumic acid has enjoyed orphan drug status since 1998 as a NAG replacement to activate CPS 1 in NAGS deficiency patients. FDA approval in 2010 was granted on the basis of the retrospective review of the clinical course of 23 patients who received treatment for a median of 7.9 years (range 0.6 to 20.8 years). Therapy with carglumic acid decreases the frequency of hyperammonemic crises and reduces the associated neurotoxicity. Information about the tolerability of carglumic acid is limited. The dose is individually titrated to ammonia levels and symptoms. Concomitant therapy with other ammonia lowering strategies is recommended.
Chemical structure of carglumic acid (PubChem CID: 121396) compared to n-acetylglutamate (PubChem CID: 70914)
Collagenase clostridium histolyticum (XIAFLEX) consists of a 1:1 ratio of two microbial collagenases isolated and from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a class I collagenase that preferentially cleaves the ends of collagen molecules and collagenase AUX-II is a class II collagenase that preferentially cleaves the center portions of collagen molecules. The drug was granted orphan drug status in the United States for Dupuytren disease in 1996. FDA approval in 2010 was based on the efficacy demonstrated during two randomized, placebo-controlled, multicenter trials involving 374 patients. Dupuytren disease is a condition in which the tendons of the hand that move the fingers become thickened and scarred by collagen deposits causing a fixed flexion deformity. When injected into a palpable Dupuytren disease cord, collagenase clostridium histolyticum hydrolyzes the collagen molecules in the cord resulting in enzymatic rupture. A follow-on office visit for a finger extension manipulation is usually necessary to reduce the contracture and daily home exercise is necessary to regain and retain range of motion following treatment. Up to three repeat injections per cord may be administered if needed. The enzymatic alternative appears to compare favorably to surgical fasciectomy/fasciotomy. Collagenase clostridium histolyticum must be administered with caution by a healthcare provider experienced with the injection procedure because enzymatic exposure external to the cord may result in permanent injury of non-targeted tissues (e.g., tendons, nerves, blood vessels). During pre-market clinical trials, at least 3 tendon ruptures were reported. Other common side effects of collagenase clostridium histolyticum are pain, swelling, bruising, and bleeding at the injection site. Foreign-protein hypersensitivity reactions are to be expected following repeat injections. In addition, patients are at risk of fainting during the post-injection finger extension procedure.
Fingolimod (Figure 2)(GILENYA) is the first oral medication for multiple sclerosis to be marketed in the United States. Fingolimod is indicated to reduce the frequency of clinical exacerbations and to delay physical disability in patients with multiple sclerosis. The drug demonstrated superiority over interferon beta-1a (AVONEX, REBIF) in both outcomes over the course of 12 months of study. Following oral administration, fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a non-specific sphingosine 1-phosphate (S1P) receptor modulator. With five S1P receptors characterized, the pharmacological actions of fingolimod-phosphate are predictably complex. For patients with multiple sclerosis, the main therapeutic benefits are thought to involve reducing the migration of lymphocytes into the central nervous system (CNS) by blocking their egress from lymph nodes. Besides this regulation of lymphocyte "trafficking," S1P receptors also are thought to play a role in the regulation of angiogenesis, neurogenesis, smooth-muscle contraction, heart rate, endothelial barrier integrity, and vascular tone (S1P-1 receptor); auditory and vestibular functioning and neuronal excitability (S1P-2 receptor); heart rate (S1P-3 receptor); smooth muscle cells lining the airways (S1P-4 receptor); and oligodendrocyte functioning in the white matter of the CNS (S1P-5 receptor).[8,9]
Consistent with the broad range of actions attributed to S1P receptors, fingolimod is associated a number of undesired effects which include: bradycardia (mean 13 beat/minute decrease in heart rate following the first dose), heart block, immunosuppression, lymphoma, serious infection, macular edema, change in visual acuity, reduction in pulmonary function, hepatic dysfunction, and hypertension. In addition to these risks, patients receiving fingolimod must be monitored for hepatotoxicity and women of childbearing potential should use effective contraception to avoid pregnancy during, and extending for 2 months after stopping, therapy with fingolimod. Untoward reactions may also occur in patients receiving antiarrhythmic drugs, beta-blockers, calcium channel blockers, antihypertensive drugs, drugs for heart failure, ketoconazole, live attenuated vaccines, antineoplastics, immunosuppressives, immune modulators, and antigenic testing concurrently with fingolimod and for up to 2 months after its discontinuation.
The recommended dose of fingolimod is 0.5 mg orally once daily. Patients should have baseline laboratories drawn before starting therapy and should be monitored for bradycardia for 6 hours after the first dose. Fingolimod is well absorbed orally with the Tmax delayed until 12-16 hours after a dose. Fingolimod is extensively distributed to body tissues with a volume of distribution of approximately 1200 ± 260 liters. Fingolimod and fingolimod-phosphate are >99% protein bound. Steady-state concentrations (approximately 10-fold greater than after the initial dose) are reached within 1 to 2 months. The half-life for elimination of fingolimod averages 6-9 days; however, the pharmacodynamic effects (including decreased lymphocyte counts) persist for up to 2 months. Fingolimod is mainly excreted in the urine as inactive metabolites. There are three pathways involved in the metabolism of fingolimod: (1) phosphorylation to the pharmacologically active fingolimod-phosphate; (2) biotransformation mainly by cytochrome P450 isozyme 4F2 (but also 2D6, 2E1, 3A4, and 4F12) with subsequent degradation to inactive metabolites; and (3) formation of inactive ceramide analogs.
Tesamorelin (Figure 3) (EGRIFTA) (PubChem # 44201342) is an analog of growth hormone-releasing hormone (GHRH) approved for reducing visceral adipose tissue in patients with HIV-associated lipohypertrophy. Tesamorelin is administered subcutaneously once daily. The drug is contraindicated in patients with disruption of the hypothalamic-pituitary axis, active malignancy, and during pregnancy (FDA pregnancy category X). Adverse effects include fluid retention, hemoglobin A1c elevation, glucose intolerance, development of diabetes, injection site reactions, and hypersensitivity reactions. Approximately 50% of patients develop anti-tesamorelin IgG antibodies and 5-10% of patients develop tesamorelin-neutralizing antibodies. Approximately 60% of anti-tesamorelin IgG antibodies are cross-reactive with endogenous growth hormone-releasing hormone. The pharmacologic effect of tesamorelin is to induce growth hormone (GH) secretion from the pituitary and secondarily to result in insulin-like growth hormone 1 (IGF-1) secretion from the liver and peripheral tissues. All of the clinical considerations for the administration of exogenous growth hormone apply. By extension, patients who are critically ill at are risk for increased mortality due to the pharmacologic effects of growth hormone, and may experience altered clearance of compounds metabolized by CYP450 liver isozymes. Careful monitoring of patients receiving concomitant therapy with CYP450 substrates is warranted, particularly patients receiving chronic corticosteroids and patients with hypoadrenalism receiving glucocorticoid replacement therapy. FDA approval of tesamorelin was on the basis of the modest (14-18%) reduction in visceral adipose tissue by week 26 of treatment. On average the reduction was demonstrated to be sustainable for up to a year of treatment with regain of the fat lost upon discontinuation of therapy. Pre-market studies were not robust enough to determine the long-term implications for cardiovascular risk in the population studied. The magnitude of fat loss with tesamorelin is similar to the results attainable through diet and exercise. Given the potential for adverse effects, patients receiving tesamorelin require careful monitoring, particularly for altered glucose metabolism.
Tocilizumab (ACTEMRA) is the 9th immunomodulator to be FDA approved for rheumatoid arthritis. Tocilizumab is the first-in-class anti-interleukin 6 (IL-6) receptor monoclonal antibody. It has been available for use in Japan since 2005. IL-6 is a pleiotropic pro-inflammatory cytokine produced by T- and B-cells, lymphocytes, monocytes, fibroblasts, and synovial and endothelial cells of joints affected by rheumatoid arthritis. Of importance, IL-6 induces osteoclast differentiation and can be responsible for joint destruction in patients suffering from rheumatoid arthritis. Tocilizumab inhibits signaling through both forms of the IL-6 receptor, sIL-6R and mIL-6R. Tocilizumab is specifically indicated for once-a-month intravenous infusion, with or without methotrexate, for patients who have failed therapy with one or more TNF antagonists. Tocilizumab shares the adverse effect profile of other monoclonal immunosuppressors, including infusion reactions, development of neutralizing antibodies, hypersensitivity reactions, elevation of the risk for serious infections and reactivation of latent infections, and the potential for development of malignancy. Laboratory monitoring of neutrophils, platelets, lipids, and liver function is necessary and the dose of tocilizumab must be adjusted on the basis of abnormal findings. Hyperlipidemia, gastrointestinal perforation, and symptoms of demyelinating disorders have been associated with tocilizumab therapy. Tocilizumab may result in a shift in the expression of hepatic CYP450 enzymes and may lead to clinically significant drug interactions with narrow therapeutic index substrates of these isozymes. The onset of action of tocilizumab is heralded by a decrease in levels of C-reactive protein within 2 weeks of the first dose. Changes in other pharmacodynamic parameters include decreases in rheumatoid factor, erythrocyte sedimentation rate, and serum amyloid A as well as increases in hemoglobin. The half-life for tocilizumab elimination is 11-12 days. The efficacy of tocilizumab was evaluated in five controlled studies of patients who had an inadequate clinical response to methotrexate, other disease-modifying antirheumatic drugs, or TNF antagonist therapy. Efficacy was measured as the percentage of patients achieving a 20% improvement in disease activity according to American College of Rheumatology criteria. While the overall response rate to tocilizumab appears to be similar to other biologics, tocilizumab is the first biologic for rheumatoid arthritis to demonstrate head-to-head superiority over methotrexate. Also similar to trials of other biologics, the response to tocilizumab trended lower with prior disease duration and prior therapeutic experience.
Ulipristal (Figure 4) (ELLA) is the first progesterone receptor modulator with antagonist and partial agonist effects. Ulipristal is approved for use as a 30 mg single-dose emergency contraceptive. Unlike levonorgestrel-based emergency contraceptives (PLAN B, PLAN B ONE STEP, NEXT CHOICE) that are available over-the-counter and must be taken within 3 days of unprotected intercourse, ulipristal is only available by prescription, but can be taken up to 5 days after unprotected intercourse. The most common adverse reactions following ulipristal are headache (18%), abdominal pain (12%), nausea (12%), dysmenorrhea (9%), fatigue (6%), dizziness (5%), and a one-time disruption to the menstrual cycle length. Due to its high affinity for the progesterone receptor, ulipristal may reduce the efficacy of regular hormonal contraceptives necessitating supplemental use of a reliable barrier contraceptive method until the onset of menses. Predominantly metabolized by CYP3A4 to mono- and di-demethylated metabolites, ulipristal also has the potential for drug-drug interactions with compounds that induce or inhibit CYP3A4. Like other progesterone agonists, the pharmacological actions of ulipristal are specific to the phase of the menstrual cycle. When taken immediately before ovulation, ulipristal postpones follicular rupture. Therefore, the most likely mechanism of action of ulipristal for emergency contraception is ovulation delay or inhibition.
AccessMedicine from McGraw-Hill © 2011
The McGraw-Hill Companies
All rights reserved. From Tintinalli's Emergency Medicine
Cite this: 2010 In Review: Synopsis of Noteworthy FDA Approvals - Medscape - May 02, 2011.